| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1074-7613(03)00326-1 |
| P698 | PubMed publication ID | 14670302 |
| P50 | author | Sheena Cruickshank | Q21264646 |
| Colin Dunstan | Q43109492 | ||
| Simon R. Carding | Q52855750 | ||
| P2093 | author name string | M J Perry | |
| P I Croucher | |||
| G J Morgan | |||
| J A Child | |||
| P J Felsburg | |||
| A J Ashcroft | |||
| J M Lippitt | |||
| S Rollinson | |||
| P2860 | cites work | CD40 AND CD154 IN CELL-MEDIATED IMMUNITY | Q22255634 |
| Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation | Q24311588 | ||
| Osteoprotegerin: a novel secreted protein involved in the regulation of bone density | Q24313918 | ||
| Development and function of T cells in mice rendered interleukin-2 deficient by gene targeting | Q24318910 | ||
| A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function | Q24336057 | ||
| RANK is essential for osteoclast and lymph node development | Q24598872 | ||
| Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma | Q77337118 | ||
| Examination, prevention and treatment of osteoporosis in patients with inflammatory bowel disease: recommendations and reality | Q78496657 | ||
| Inflammatory T cells rapidly induce differentiation of human bone marrow stromal cells into mature osteoblasts | Q78955391 | ||
| Interleukin-2 stimulates osteoclastic activity: increased acid production and radioactive calcium release | Q93520066 | ||
| The molecular mechanism of osteoclastogenesis in rheumatoid arthritis | Q24806322 | ||
| RANK-L and RANK: T cells, bone loss, and mammalian evolution | Q28203468 | ||
| The TNF and TNF receptor superfamilies: integrating mammalian biology | Q28203717 | ||
| The clinical impact of metabolic bone disease in coeliac disease | Q28345283 | ||
| OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis | Q28589430 | ||
| Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene | Q28593669 | ||
| Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand | Q29619331 | ||
| Development and maturation of secondary lymphoid tissues. | Q33652498 | ||
| Immunopathology of interleukin (IL) 2-deficient mice: thymus dependence and suppression by thymus-dependent cells with an intact IL-2 gene | Q34719199 | ||
| IL-2 and autoimmune disease | Q34830619 | ||
| The dendritic cell: its role in intestinal inflammation and relationship with gut bacteria | Q35217282 | ||
| High prevalence of osteoporotic vertebral fractures in patients with Crohn's disease | Q35595126 | ||
| TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo | Q36375923 | ||
| TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor | Q36380989 | ||
| RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism | Q37108966 | ||
| Osteoprotegerin, a crucial regulator of bone metabolism, also regulates B cell development and function | Q38525468 | ||
| Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin | Q39116155 | ||
| Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone | Q39946634 | ||
| Interleukin-2 and human monocyte activation. | Q40575900 | ||
| The effect of a single dose of osteoprotegerin in postmenopausal women | Q43520860 | ||
| Corticosteroid-induced osteoporosis: does it occur in patients with Crohn's disease? | Q44110692 | ||
| Metabolic bone disease is present at diagnosis in patients with inflammatory bowel disease | Q44186830 | ||
| Langerhans cell histiocytosis in children: does soluble interleukin-2-receptor correlate with both disease extent and activity? | Q47780281 | ||
| T Cell Activation Induces Human Osteoclast Formation via Receptor Activator of Nuclear Factor κB Ligand-Dependent and -Independent Mechanisms | Q60524745 | ||
| Mechanism of hypercalcemia in adult T-cell leukemia: overexpression of receptor activator of nuclear factor kappa B ligand on adult T-cell leukemia cells | Q63384151 | ||
| Interleukin-2 production and bone-resorption activity in vitro by unstimulated lymphocytes extracted from chronically-inflamed human periodontal tissues | Q69874208 | ||
| Relationship between soluble markers of immune activation and bone turnover in post-menopausal women with rheumatoid arthritis | Q73069498 | ||
| Activated T lymphocytes support osteoclast formation in vitro | Q73149439 | ||
| Colonic lamina propria dendritic cells in mice with CD4+ T cell-induced colitis | Q73207489 | ||
| Migration and maturation of human colonic dendritic cells | Q73720830 | ||
| Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord | Q73766127 | ||
| Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone | Q73835736 | ||
| Regulation of mucosal dendritic cell function by receptor activator of NF-kappa B (RANK)/RANK ligand interactions: impact on tolerance induction | Q74817249 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 849-861 | |
| P577 | publication date | 2003-12-01 | |
| P1433 | published in | Immunity | Q6005457 |
| P1476 | title | Colonic dendritic cells, intestinal inflammation, and T cell-mediated bone destruction are modulated by recombinant osteoprotegerin. | |
| P478 | volume | 19 |
| Q27005894 | A review of denosumab for the treatment of osteoporosis |
| Q37342592 | A single-nucleotide polymorphism in the gene encoding osteoprotegerin, an anti-inflammatory protein produced in response to infection with diarrheagenic Escherichia coli, is associated with an increased risk of nonsecretory bacterial diarrhea in Nor |
| Q34597741 | Advances in the understanding of mineral and bone metabolism in inflammatory bowel diseases |
| Q34225188 | Basic and clinical aspects of osteoporosis in inflammatory bowel disease. |
| Q92685563 | Bone alterations in inflammatory bowel diseases |
| Q37936285 | Bone, inflammation, and inflammatory bowel disease. |
| Q28245649 | Cerebral ischemia increases bone marrow CD4+CD25+FoxP3+ regulatory T cells in mice via signals from sympathetic nervous system |
| Q35059555 | Characterization of colonic dendritic cells in normal and colitic mice |
| Q37047867 | Chronic pediatric inflammatory diseases: effects on bone |
| Q97518627 | Denosumab Regulates Gut Microbiota Composition and Cytokines in Dinitrobenzene Sulfonic Acid (DNBS)-Experimental Colitis |
| Q34545263 | Denosumab: targeting the RANKL pathway to treat rheumatoid arthritis. |
| Q37767159 | Do RANKL inhibitors (denosumab) affect inflammation and immunity? |
| Q41492918 | Emerging Roles for Noncanonical NF-κB Signaling in the Modulation of Inflammatory Bowel Disease Pathobiology |
| Q57184743 | Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells |
| Q24653651 | Exaggerated inflammatory response of primary human myeloid dendritic cells to lipopolysaccharide in patients with inflammatory bowel disease |
| Q35740351 | Extraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medications |
| Q27021773 | Fecal biomarkers of intestinal health and disease in children |
| Q51021843 | Fecal osteoprotegerin may guide the introduction of second-line therapy in hospitalized children with ulcerative colitis. |
| Q38001203 | Fine-tuning of dendritic cell biology by the TNF superfamily |
| Q36292836 | IBD and skeletal health: children are not small adults! |
| Q38113210 | Immunology and bone |
| Q81009343 | Increased expression of receptor activator of NF-kappaB ligand (RANKL), its receptor RANK and its decoy receptor osteoprotegerin in the colon of Crohn's disease patients |
| Q47442534 | Inflammatory Bowel Disease: Effects on Bone and Mechanisms |
| Q33762244 | Inflammatory bowel disease causes reversible suppression of osteoblast and chondrocyte function in mice. |
| Q33284507 | Inflammatory bowel disease: cause and immunobiology |
| Q36565219 | Inflammatory bowel diseases as secondary causes of osteoporosis |
| Q47975714 | Inflammatory diseases and bone fragility |
| Q39645392 | Interleukin-33 is expressed in differentiated osteoblasts and blocks osteoclast formation from bone marrow precursor cells |
| Q92051810 | Mechanisms Underlying Bone Loss Associated with Gut Inflammation |
| Q37361936 | New insights into the roles of dendritic cells in intestinal immunity and tolerance |
| Q40044243 | Normal human primary CD4+ T lymphocytes synthesize and release functional osteoprotegerin in vitro |
| Q36324916 | Osteoclast precursors, RANKL/RANK, and immunology |
| Q37489600 | Osteoclasts and the immune system |
| Q26770666 | Osteoimmune Interactions in Inflammatory Bowel Disease: Central Role of Bone Marrow Th17 TNFα Cells in Osteoclastogenesis |
| Q88248494 | Osteoimmunology |
| Q37949580 | Osteoimmunology - Unleashing the concepts |
| Q37626412 | Osteoimmunology and the effects of the immune system on bone |
| Q47944184 | Osteoimmunology: The Conceptual Framework Unifying the Immune and Skeletal Systems. |
| Q37544448 | Osteoimmunology: crosstalk between the immune and bone systems |
| Q24655113 | Osteoimmunology: interactions of the bone and immune system |
| Q28294477 | Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems |
| Q37756576 | Osteoporosis and inflammation |
| Q53619763 | Osteoprotegerin Levels Decrease in Abstinent Alcohol-Dependent Patients. |
| Q38741874 | Osteoprotegerin: A novel biomarker for inflammatory bowel disease and gastrointestinal carcinoma. |
| Q34248293 | Perforin-dependent elimination of dendritic cells regulates the expansion of antigen-specific CD8+ T cells in vivo |
| Q36569260 | Prevention and treatment of osteoporosis in inflammatory bowel disease |
| Q36134061 | Quantitation of the Rank-Rankl Axis in Primary Biliary Cholangitis |
| Q38691526 | RANK as a therapeutic target in cancer. |
| Q43004256 | RANK ligand and osteoprotegerin: emerging roles in mucosal inflammation. |
| Q36412789 | RANKL-RANK interaction in immune regulatory systems |
| Q42007164 | Rapid dendritic cell mobilization to the large intestinal epithelium is associated with resistance to Trichuris muris infection |
| Q37362936 | Regulation of dendritic cell survival and cytokine production by osteoprotegerin |
| Q44192941 | Serum osteoprotegerin is increased in Crohn's disease: a population-based case control study |
| Q85849560 | Serum osteoprotegerin is markedly increased and may contribute to decreased blood T cell count in hemodialysis patients |
| Q38009712 | Skeletal and extraskeletal actions of denosumab. |
| Q37376421 | Systemic release of osteoprotegerin during oxaliplatin-containing induction chemotherapy and favorable systemic outcome of sequential radiotherapy in rectal cancer |
| Q35597297 | The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss |
| Q88954027 | The Tumor Necrosis Factor Superfamily Member RANKL Suppresses Effector Cytokine Production in Group 3 Innate Lymphoid Cells |
| Q36324969 | The role of the immune system in the pathophysiology of osteoporosis |
| Q52858571 | Toll-like receptor-mediated responses of primary intestinal epithelial cells during the development of colitis. |
Search more.